Your shopping cart is currently empty

AM-0883 is an agonist of TRPC6 (transient receptor potential canonical 6) with a human TRPC6 EC50 of 46 nM. It is applicable for research in cardiac and renal diseases.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | AM-0883 is an agonist of TRPC6 (transient receptor potential canonical 6) with a human TRPC6 EC50 of 46 nM. It is applicable for research in cardiac and renal diseases. |
| Targets&IC50 | TRPC6 (human):46 nM (EC50) |
| In vitro | AM-0883 activates wild-type TRPC6 in HEK293T cells with an EC50 of 45.5 nM and the N-terminal truncated mutant TRPC6 (Δ2–72) in HEK293T cells with an EC50 of 90.2 nM. It activates the channel through specific residues at the S6/pore helix junction. AM-0883 exhibits significantly stronger activation of the V867T/L868T double mutant compared to the wild-type channel. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.